trending Market Intelligence /marketintelligence/en/news-insights/trending/-4alJFhpgPzWg2D38_UmYQ2 content esgSubNav
In This List

Protagonist Therapeutics names board member

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Protagonist Therapeutics names board member

Protagonist Therapeutics Inc. appointed Bryan Giraudo to its board.

Giraudo also serves as CFO of Gossamer Bio Inc. Previously, he worked at Leerink Partners as senior managing director, in charge of western North America and Asia biotechnology and pharmaceutical relationships.

Protagonist Therapeutics is a Newark, Calif.-based biopharmaceutical company, whose product pipeline includes therapies for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.